US-Based Emmes Acquires VaxTRIALS
Press Release
This strategic acquisition is part of Emmes’ broader objective to expand its global presence beyond its existing operations in North America, Europe, and Asia into the Latin American market. The move is expected to strengthen Emmes’ expertise in one of its core research focus areas: vaccines and infectious diseases.
US-based Clinical Research Organisation (CRO) Emmes has acquired VaxTRIALS, a specialised Clinical Research Organisation headquartered in Panama City.
While the financial terms of the acquisition have not been publicly disclosed, the transaction was finalised on October 5, 2023.
By expanding into Latin America, Emmes aims to enhance its global clinical trial capabilities and deepen its experience in vaccine and infectious disease research.
Commenting on the acquisition, Dr José Jimeno, Chief Executive Officer of VaxTRIALS, said: “Both our companies have built enduring customer relationships and a legacy of service in vaccine and infectious disease research. I am excited to incorporate Emmes’ technology expertise, as well as its long-standing strength in biostatistical analysis and data management, for the benefit of our clients throughout Latin America. Emmes’ Advantage eClinical data management platform—designed to improve data quality, simplify oversight of clinical trial operations, and reduce trial timelines and costs—will be extremely valuable to our customers.”
Headquartered in Panama City, VaxTRIALS is a specialised Clinical Research Organisation founded in 2012. The company provides advanced solutions for managing and monitoring vaccine clinical trial activities across Latin America and the Philippines. VaxTRIALS supports research aimed at preventing diseases such as influenza, dengue, chikungunya, hepatitis A, meningitis, norovirus, herpes zoster, pertussis, respiratory syncytial virus (RSV), polio, and COVID-19.
Sharing his views, Sastry Chilukuri, Executive Chairman of Emmes, said: “Today’s clinical trials are more complex and more global than ever before. By combining VaxTRIALS’ deep expertise in Latin America with Emmes’ strengths in technology, biostatistics, and data management, we can offer clients an unmatched partnership experience in conducting their clinical trials.”
Founded in 1977, Emmes is a global, full-service Clinical Research Organization (CRO) that has conducted more than 2,000 clinical studies across a broad range of therapeutic areas. The company has significant expertise in infectious diseases, vaccines, ophthalmology, oncology, neurology, substance use disorders, and maternal and child health. Emmes employs more than 1,000 professionals across the United States, Europe, Canada, and India, with annual revenues estimated between $100 million and $500 million.
Recently, Emmes appointed Matt Bond as Chief Financial Officer to support its mission of advancing public health and biopharmaceutical innovation.
In addition, the company appointed Peter Ronco as Chief Executive Officer, succeeding Dr. Christine Dingivan, who transitioned to the role of Senior Advisor to Executive Chairman Sastry Chilukuri and Emmes’ Board of Directors.
Go back to Newsroom
This strategic acquisition is part of Emmes’ broader objective to expand its global presence beyond its existing operations in North America, Europe, and Asia into the Latin American market. The move is expected to strengthen Emmes’ expertise in one of its core research focus areas: vaccines and infectious diseases.
US-based Clinical Research Organisation (CRO) Emmes has acquired VaxTRIALS, a specialised Clinical Research Organisation headquartered in Panama City.
While the financial terms of the acquisition have not been publicly disclosed, the transaction was finalised on October 5, 2023.
By expanding into Latin America, Emmes aims to enhance its global clinical trial capabilities and deepen its experience in vaccine and infectious disease research.
Commenting on the acquisition, Dr José Jimeno, Chief Executive Officer of VaxTRIALS, said: “Both our companies have built enduring customer relationships and a legacy of service in vaccine and infectious disease research. I am excited to incorporate Emmes’ technology expertise, as well as its long-standing strength in biostatistical analysis and data management, for the benefit of our clients throughout Latin America. Emmes’ Advantage eClinical data management platform—designed to improve data quality, simplify oversight of clinical trial operations, and reduce trial timelines and costs—will be extremely valuable to our customers.”
Headquartered in Panama City, VaxTRIALS is a specialised Clinical Research Organisation founded in 2012. The company provides advanced solutions for managing and monitoring vaccine clinical trial activities across Latin America and the Philippines. VaxTRIALS supports research aimed at preventing diseases such as influenza, dengue, chikungunya, hepatitis A, meningitis, norovirus, herpes zoster, pertussis, respiratory syncytial virus (RSV), polio, and COVID-19.
Sharing his views, Sastry Chilukuri, Executive Chairman of Emmes, said: “Today’s clinical trials are more complex and more global than ever before. By combining VaxTRIALS’ deep expertise in Latin America with Emmes’ strengths in technology, biostatistics, and data management, we can offer clients an unmatched partnership experience in conducting their clinical trials.”
Founded in 1977, Emmes is a global, full-service Clinical Research Organization (CRO) that has conducted more than 2,000 clinical studies across a broad range of therapeutic areas. The company has significant expertise in infectious diseases, vaccines, ophthalmology, oncology, neurology, substance use disorders, and maternal and child health. Emmes employs more than 1,000 professionals across the United States, Europe, Canada, and India, with annual revenues estimated between $100 million and $500 million.
Recently, Emmes appointed Matt Bond as Chief Financial Officer to support its mission of advancing public health and biopharmaceutical innovation.
In addition, the company appointed Peter Ronco as Chief Executive Officer, succeeding Dr. Christine Dingivan, who transitioned to the role of Senior Advisor to Executive Chairman Sastry Chilukuri and Emmes’ Board of Directors.